Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Current Quarter	$-0.17	Next Quarter	$0.05
Current Year	$0.14	Next Year	$0.34
QoQ Growth	+129.4%	YoY Growth	+142.9%
3Y EPS CAGR	+42.0%	Target Price	$3.50
Consensus	Buy	Upside	-53.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PBYI	$7.44	+6.74%	356.80K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PBYI	$7.44	+6.7%	356.80K
3
4
5
6

PBYI

PBYI

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Puma Biotechnology Inc Data in Excel

Get Puma Biotechnology Inc Data in Excel